Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

Jennifer Edelmann; Jitka Malcikova; John C Riches

doi:10.3389/fonc.2023.1106579

Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

Front Oncol. 2023 Feb 9:13:1106579. doi: 10.3389/fonc.2023.1106579. eCollection 2023.

Authors

Jennifer Edelmann¹, Jitka Malcikova^{2

3}, John C Riches^{4

5}

Affiliations

¹ ClinSciNet - The Clinician Scientist Network, Münsingen, Germany.
² Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czechia.
³ Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czechia.
⁴ Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
⁵ Department of Haemato-Oncology, Barts Health NHS Trust, St. Bartholomew's Hospital, London, United Kingdom.

No abstract available

Keywords: BCL2 (B-cell lymphoma 2); BTK - Bruton’s tyrosine kinase; COVID - 19; TP53; chronic lymphocytic leukemia (CLL); definition; high-risk; risk factor.

Grants and funding

JM was supported by the project Conceptual development of research organization (FNBr 6526975) provided by the Ministry of Health of the Czech Republic and by the National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102) funded by the European Union – Next Generation EU.